Catalog No.
Product Name
Application
Product Information
Citations
-
HIV Entry Inhibitor
BMS-806, also known as BMS-378806 , is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells. BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection. -
TNF receptor inhibitor
AX-024 is an orally available inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation (IC50 value 1 nM). Inhibiting an immediate TCR signal has promise for treating a broad spectrum of human T cell-mediated autoimmune and inflammatory diseases. -
CD38 inhibitor
CD38 inhibitor 1 (compound 78c) is a potent CD38 inhibitor with IC50s of 7.3 nM and 1.9 nM for hCD38 and mouse CD38. -
NTPDase inhibitor
Sodium metatungstate (POM-1) is a potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitor, with Ki values of 2.58 μM, 3.26 μM, and 28.8 μM for NTPDase 1, NTPDase 3 and NTPDase 2 respectively. -
CD73 Inhibitor
LY-3475070 is a potent and selective CD73 Inhibitor with IC50 of 28 nM. - PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects.
-
CD38 inhibitor
MK-0159 is an orally active, potent, and selective inhibitor of CD38, with IC₅₀ values of 22 nM for human, 3 nM for mouse, and 70 nM for rat CD38. It exhibits good microsomal stability in both human and rodent liver microsomes. MK-0159 effectively increases NAD⁺ (nicotinamide adenine dinucleotide) levels and decreases ADPR (adenosine diphosphate ribose) concentrations in whole blood and heart tissue, making it a promising compound for research in metabolic, cardiovascular, and age-related diseases. -
CD11b agonist.
ADH-503 ((Z)-Leukadherin-1 choline) is an orally active, allosteric agonist of CD11b, an integrin subunit expressed on myeloid cells. By activating CD11b, ADH-503 promotes the repolarization of tumor-associated macrophages (TAMs) toward a pro-inflammatory phenotype, reduces the infiltration of immunosuppressive myeloid cells into tumors, and enhances dendritic cell responses. These immunomodulatory effects support its potential use in cancer immunotherapy. -
CD38 inhibitor
RBN013209 is an orally active, small molecule inhibitor of CD38, exhibiting potent inhibitory activity with an IC₅₀ ranging from 0.01 to 0.1 μM against human CD38. It effectively blocks the enzymatic conversion of extracellular NAD⁺ to ADPR and cADPR in both tumor cells and peripheral blood mononuclear cells (PBMCs), thereby modulating the tumor microenvironment. Beyond its direct antitumor potential, RBN013209 also enhances the efficacy of immunotherapies. It preserves the naïve and central memory phenotypes of CAR-T cells, while reducing the expression of activation markers and exhaustion-associated inhibitory receptors. These properties position RBN013209 as a promising agent for both tumor research and the development of combination strategies to improve CAR-T cell persistence and function. -
CD206 Targeting Peptide
RP-182 is a synthetic immunomodulatory peptide that targets the mannose receptor CD206 on tumor-associated macrophages (TAMs), exhibiting a dissociation constant (Kd) of 8 μM. By inducing a conformational change in the CD206 receptor, RP-182 activates NF-κB signaling, promoting TNFα secretion and phagocytosis in CD206high TAMs, ultimately leading to apoptosis via caspase 8 activation. This compound is valuable for research in pancreatic cancer and melanoma, providing insights into therapeutic strategies that enhance anti-tumor immunity. -
Anti-TNFRSF17/CD3E Antibody
Gamgertamig is a humanized IgG4 bispecific antibody that simultaneously targets TNFRSF17 and CD3E. This antibody exhibits potent immunomodulatory activity by activating T cells in the presence of TNFRSF17-expressing cells, making it a valuable tool for enhancing anti-tumor immune responses. It is ideal for research applications in cancer immunotherapy and provides insights into T cell modulation and tumor microenvironment interactions. -
CD28 Inhibitor
CD28-IN-3 is a selective CD28 inhibitor that effectively interrupts the CD28-B7 interaction, with an IC50 of 7.80 μM and a Kd of 52.45 μM. This compound significantly suppresses the production of key proinflammatory cytokines, including IFN-γ, IL-2, and TNF-α. CD28-IN-3 is valuable for research focused on checkpoint-resistant cancers, providing insights into immune modulation and potential therapeutic strategies. -
CD28 Inhibitor
CD28-IN-1 is a selective inhibitor of CD28 with a dissociation constant (KD) of 12.48 μM. It effectively disrupts the CD28-B7 interactions, leading to a significant reduction in CD28-mediated immune activation. This compound has been shown to suppress cytokine production, including IFN-γ, IL-2, and TNF-α, in primary human T cells when co-cultured with tumor spheroids and human epithelial tissues. CD28-IN-1 is suitable for research focused on tumor immunity and T cell modulation. -
Anti-CD274/TNFRSF9 Antibody
Solabafusp alfa is a humanized IgG4κ type antibody that specifically targets CD274 (also known as PD-L1) and TNFRSF9 (also known as 4-1BB). This compound is significant for its potential to modulate immune responses, making it a valuable tool in cancer research and immunotherapy studies. It can be utilized to explore pathways related to immune checkpoint inhibition and T-cell activation. An appropriate isotype control for this antibody is Human IgG4 (S228P) kappa. -
CD206 Targeting Peptide
RP-832c is a synthetic analogue of host defense peptides that selectively targets the mannose receptor CD206 on M2 polarized macrophages (Kd = 3.5 μM). Binding of RP-832c to CD206 induces significant conformational changes, activating signaling pathways that promote apoptosis and repolarization of M2 macrophages to an M1 phenotype. The treatment with RP-832c effectively reduces CD206 gene expression while transiently increasing TNF-α levels, a hallmark of M1 macrophages. This reagent is valuable for research on T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF). -
CD27 Agonist
MG-C-30 is a potent oral agonist of CD27, demonstrating an EC50 of 0.84 μM. This compound activates natural killer (NK) cells and enhances T cell co-stimulatory signals, thereby augmenting the immune response. MG-C-30 has also shown significant antitumor efficacy in the EG7-OVA mouse model, making it a valuable tool for research in immunotherapy and cancer treatment. -
GPRC5D/CD3ε/TNFRSF17 Antibody
Ramantamig is a humanized monoclonal antibody that targets CD3ε on T cells, as well as GPRC5D and TNFRSF17 (BCMA) on multiple myeloma cells. It facilitates T-cell-mediated cytotoxicity by forming immunological synapses, leading to selective killing of myeloma cells without non-specific T-cell activation when target cells are absent. Additionally, Ramantamig has been engineered to minimize interactions with Fc receptors, enhancing its specificity. This reagent is ideal for research in multiple myeloma therapies. -
Anti-EGFR/CD47 Antibody
Vislarafusp alfa is a humanized IgG1κ antibody targeting both EGFR and CD47. This novel bispecific antibody exhibits potential for modulating tumor immune evasion and promoting anti-tumor responses, making it significant in cancer research applications. Its unique mechanism of action presents valuable opportunities for studying combination therapies and understanding the interplay between immune checkpoint regulators and growth factor signaling pathways. -
NCD38 Enantiomer
(1R,2S)-NCD38 TFA is a selective inhibitor of Lysine-specific demethylase 1 (LSD1). This enantiomeric form of NCD38 TFA exhibits potent biological activity, primarily in the modulation of epigenetic regulation through LSD1 inhibition. It is applicable in research focused on cancer biology, developmental studies, and potential therapeutic interventions targeting LSD1-related pathways. -
CD47-SIRPα axis Inhibitor
DMUP is a potent inhibitor of the CD47-SIRPα axis. This compound promotes apoptosis and enhances macrophage phagocytosis in A549 lung cancer cells, while also reducing the expression of CD47 and SIRPα proteins. DMUP demonstrates significant antitumor activity, making it a valuable tool for research in cancer immunotherapy and macrophage biology. -
CD47 Agonist
Thrombospondin-1 (1016-1023) is a peptide derived from the C-terminal region of Thrombospondin-1 (TSP-1) and functions as a CD47 agonist. This peptide plays a crucial role in modulating immune responses and promoting cell survival by interacting with the CD47 receptor. It is widely utilized in research focusing on immunology, cancer biology, and the study of cell migration and adhesion. -
CD37-Targeted ADC
Naratuximab emtansine is a CD37-targeted antibody-drug conjugate (ADC) that combines a humanized IgG1 monoclonal antibody with the microtubule disruptor DM1. This compound exhibits high affinity and specificity for the CD37 antigen, facilitating internalization and subsequent release of DM1 intracellularly. By disrupting microtubule assembly, Naratuximab emtansine leads to cell cycle arrest and apoptosis, making it a valuable tool for research in targeted cancer therapies and hematological malignancies. -
Anti-CD20 Antibody
Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 antibody targeting the CD20 antigen on B cells. This antibody exhibits significant pro-apoptotic activity in vitro and mediates both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). In various tumor xenograft models, mAb 1.5.3 demonstrates enhanced anti-tumor efficacy. Additionally, it achieves superior B-cell depletion in lymphoid tissues and bone marrow in primate pharmacodynamic studies, making it a valuable tool for research into B-cell malignancies. -
Anti-CD37 Antibody
BI-836826 is a chimerized IgG1 monoclonal antibody targeting CD37. This antibody exhibits both antibody-dependent cell-mediated cytotoxicity (ADCC) and direct pro-apoptotic effects, making it a valuable tool for investigating chronic lymphocytic leukemia. Its unique properties facilitate research into therapeutic applications and mechanisms of action related to CD37 in lymphoid malignancies. -
PDCD1/PD-1/CD279 Antibody
Liscastobart is a humanized IgG4κ antibody that specifically targets the programmed cell death protein 1 (PDCD1/PD-1/CD279). This antibody is instrumental in studies aimed at understanding immune regulation and checkpoint inhibition, making it valuable for cancer immunotherapy research. Its application includes assessing PD-1 blockade effects in various in vitro and in vivo models. -
interleukin-2 receptor alpha (CD25) Targeting Agent, Treg Expander
Melredableukin alfa is a bivalent conjugate targeting the interleukin-2 receptor alpha (CD25) and acts as a Treg expander. This compound demonstrates enhanced selectivity for regulatory T cells in cynomolgus monkey and humanized mouse models. Melredableukin alfa is utilized in research related to autoimmune conditions, including ulcerative colitis and autoimmune hepatitis, enabling exploration of Treg cell modulation in therapeutic contexts. -
CD47-SIRPα Signalling Inhibitor
RS17 is a CD47-SIRPα signaling inhibitor that disrupts the interaction between CD47 and its ligand, SIRPα, on macrophage surfaces. By binding to CD47, RS17 prevents the transmission of signals that enable selective phagocytosis, thereby promoting the recognition and clearance of tumor cells by macrophages. This peptide is valuable for researching anti-tumor responses and mechanisms of immune evasion in cancer. -
CD25 ADC
Camidanlumab tesirine is an antibody-drug conjugate (ADC) that targets CD25, utilizing the HuMax-TAC human IgG1 monoclonal antibody. This compound is conjugated via a cleavable dipeptide linker to a pyrrolobenzodiazepine (PBD) dimer, achieving a drug-antibody ratio of 2.3. Camidanlumab tesirine demonstrates exceptional affinity for human CD25 at the picomolar level and exhibits potent cytotoxic effects against various CD25-expressing human lymphoma cell lines, positioning it as a promising candidate for targeted cancer therapies. -
CD44-Hyaluronan Inhibitor
IGFBP-3 peptide is an 18-amino acid fragment of insulin-like growth factor binding protein-3, known to inhibit the interaction between CD44 and hyaluronan. This peptide effectively binds to Humanin and hyaluronan, thereby blocking their functional interactions. IGFBP-3 peptide serves as a useful tool for researching CD44-related signaling pathways and its role in cellular adhesion and migration. -
CD31 Agonist
P8RI is a biomimetic peptide that acts as a CD31 agonist. By binding to the juxtamembrane amino acid sequence of the ectodomain of CD31, P8RI restores the CD31 inhibitory pathway, exhibiting significant immunosuppressive effects. This compound is useful for research applications focused on immune modulation and the exploration of CD31-related pathways in cellular processes. -
Anti-VEGFR2/KDR/CD309 Antibody
Girancitug is a humanized IgG1κ monoclonal antibody that specifically targets the vascular endothelial growth factor receptor 2 (VEGFR2/KDR/CD309). It effectively inhibits angiogenesis, making it a valuable tool in cancer research. Girancitug is applicable in anti-angiogenic therapy studies, particularly for cancers such as colorectal and ovarian cancers. -
CD11b Agonist
(Z)-Leukadherin-1 is a potent allosteric agonist of CD11b that exhibits oral bioavailability. This compound effectively repolarizes tumor-associated macrophages, diminishes the presence of immunosuppressive myeloid cells within tumors, and enhances the activation of dendritic cells. It serves as a valuable reagent for research in immuno-oncology, exploring mechanisms of immune modulation and macrophage plasticity. -
SARM1 Activator/CD38 Inhibitor
Sulfo-ara-F-NMN is a selective SARM1 activator and CD38 inhibitor, functioning as a mimetic of nicotinamide mononucleotide (NMN). It effectively activates SARM1 while inhibiting CD38, with an IC50 of approximately 10 μM. This compound is valuable for research applications focused on the modulation of intracellular cyclic ADP-ribose (cADPR) production and the exploration of pathways involving SARM1 and CD38 in cellular signaling. -
CD45/CD148 Tyrosine Phosphatase Inhibitor
RWJ-60475 is a selective inhibitor of CD45 and CD148 tyrosine phosphatases, exhibiting an IC50 of 3.3 μM. By inhibiting these phosphatases, RWJ-60475 disrupts the phagocytic activity of macrophages, effectively blocking the invasion of Legionella pneumophila and the subsequent transport of effector proteins. This compound is valuable for research applications focused on anti-infection strategies that target host cellular factors. -
Anti-CD26 Antibody
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody that acts by inducing nuclear translocation of CD26 via the caveolin pathway. This antibody exhibits significant anti-proliferative effects on tumor cells by delaying the G2/M cell cycle transition. Additionally, YS110 is capable of inhibiting the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the interaction between MERS CoV S1 and CD26. It is a valuable tool for research applications in cancer biology and viral infections, including studies related to malignant mesothelioma and MERS. -
CD47 Agonist Peptide
Cys-PKHB1 is a CD47 agonist peptide designed to mimic thrombospondin-1. This compound has demonstrated antitumor efficacy by inducing mitochondrial alterations, the generation of reactive oxygen species (ROS), and calcium-dependent cell death in breast cancer cells. Cys-PKHB1 also promotes immune activation through immunogenic cell death, making it a valuable tool for research in cancer immunotherapy and tumor biology. -
anti-CD22-Calecheamicin Conjugate
Inotuzumab ozogamicin is an antibody-drug conjugate targeting CD22, composed of a humanized anti-CD22 antibody linked to the cytotoxic agent Calicheamicin. This compound exhibits potent efficacy against CD22-positive B-cell non-Hodgkin’s lymphoma and is being investigated for its potential in treating acute lymphoblastic leukemia. Researchers can utilize Inotuzumab ozogamicin to explore therapeutic strategies for CD22-expressing malignancies. -
CD206 Targeted Fluorescent Dye
MR2-cy5 is a fluorescent dye specifically designed to target CD206, a receptor expressed on macrophages. This reagent enables precise tracking of CD206+ macrophages in various biological samples, facilitating studies in immunology and cellular biology. MR2-cy5 is ideal for applications such as flow cytometry and imaging, contributing to the understanding of macrophage function and behavior in health and disease. -
TNFSF13B/BAFF/CD257 Inhibitor
Aritinercept is a recombinant fusion protein that functions as an inhibitor of TNFSF13B (BAFF/CD257). This compound effectively neutralizes BAFF and APRIL, leading to reduced B cell proliferation and suppression of peripheral B cells, along with a decrease in serum immunoglobulins. Aritinercept has demonstrated beneficial effects in a mouse model of systemic lupus erythematosus (SLE) by lowering markers of renal damage, as well as reducing levels of IFNγ, IL-17A, and anti-dsDNA autoantibodies. This reagent is suitable for research focused on systemic lupus erythematosus and related autoimmune disorders.
